O-Glycan-dependent Immunotherapy for Cancer

O-聚糖依赖性癌症免疫疗法

• 批准号: 9988594
• 负责人: MICHAEL DEMETRIOU
• 金额: $ 0.21万
• 依托单位: GLYTR THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-18 至 2021-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9988594
• 关键词: Address; Antibodies; Antigens; B lymphoid malignancy; Binding; Binding Proteins; Bite; Blood group antigen S; CD3 Antigens; Carbohydrates; Cell Surface Proteins; Cell surface; Cells; Clinical; Complex; Data; Development; Engineering; Excision; Funding; Galactose; Generations; Hematologic Neoplasms; Hematopoietic Neoplasms; Human; Immune; Immunotherapeutic agent; Immunotherapy; In Vitro; In complete remission; Individual; Lectin; Link; Lymphocyte; Malignant - descriptor; Malignant Neoplasms; Mediating; Monoclonal Antibodies; Normal Cell; Normal tissue morphology; Operative Surgical Procedures; Polysaccharides; Proteins; Radiation therapy; Safety; Sensitivity and Specificity; Solid; Stem cells; T-Lymphocyte; Technology; Testing; Therapeutic; Time; Tn antigen; Toxic effect; Tumor Antigens; Tumor-Associated Carbohydrate Antigens; Work; base; bi-specific T cell engager; cancer cell; cancer immunotherapy; cancer therapy; cancer type; chemotherapy; chimeric antigen receptor; chimeric antigen receptor T cells; cost; drug development; experimental study; glycosylation; macrophage; new technology; novel; novel strategies; prevent; sugar; tumor

Abstract For decades, the treatment of cancer has relied on surgical resection, chemotherapy and/or radiotherapy. Recently, a number of immune based therapies have provided promising new approaches for cancer treatment. The two most potent immunotherapies are monoclonal antibody (mAB) based bi-specific proteins (eg Bi- specific T cell engagers – BiTE) and engineered Chimeric Antigen Receptor T cells (CAR T). Both act by inducing T cell mediated killing of cancer cells and have shown remarkable clinical activity, with complete response rates as high as ~90% for B cell malignancies. However, applying these two therapeutic approaches to the vast majority of cancer types is prevented by multiple factors. First, there are only a small number of known cell-surface proteins that are sufficiently specific to cancer to safely allow targeting by antibodies. This is particularly true for solid cancers, where unlike hematopoietic malignancies, loss of healthy cells cannot be readily replenished by stem cell progenitors. Second, as each individual bi-specific protein and/or CAR T cell can only target a single cancer type, different bi-specific and/or CAR T cells will need to be developed for each cancer type. This greatly increases development time and costs. Third, neither therapy is able to effectively target the most abundant and widely expressed cancer antigens known, namely Tumor associated cancer antigens (TACA's). Many cancer specific antigens are not proteins, but rather complex carbohydrates that have limited or no expression in normal tissues. Indeed, altered glycosylation is a near universal feature of cancer. However, generation of monoclonal antibodies specific to complex carbohydrates has proven to be very challenging, greatly limiting their usefulness as targets for cancer immunotherapy. Here we propose to address these issues and develop a novel class of immunotherapeutics that target a carbohydrate antigen common to the vast majority of solid and hematopoietic cancers but not expressed in normal cells. We have termed these molecules as Glycan-dependent T cell Recruiter (GlyTR) technology. Critically, GlyTR technology does not utilize antibodies to target carbohydrate cancer antigens. Preliminary data demonstrates that an O-linked carbohydrate targeted bi-specific GlyTR protein induces T cell dependent killing of human cancer cells in vitro without off-target killing of normal cells. To further develop this technology, we propose the following Aims. Aim 1 optimizes an O-linked glycan targeted GlyTR bi-specific protein for activity and drug development. Aim 2 explores the efficacy and safety of the optimized O-linked glycan targeted GlyTR bi-specific protein. If successful, this work will lead to IND enabling studies of an entire new class of immunotherapeutic cancer killing therapeutics that can target multiple solid and hematopoietic cancers with minimal toxicity.

摘要 几十年来，癌症的治疗一直依赖于手术切除、化疗和/或放疗。 最近，许多基于免疫的疗法为癌症治疗提供了有前途的新方法。 两种最有效的免疫疗法是基于单克隆抗体（mAB）的双特异性蛋白（例如双特异性抗体）。 特异性T细胞嵌合体- BiTE）和工程化嵌合抗原受体T细胞（CAR T）。两者都是通过 诱导T细胞介导的癌细胞杀伤，并显示出显著的临床活性， 对B细胞恶性肿瘤的应答率高达~90%。然而，应用这两种治疗方法， 绝大多数癌症类型是由多种因素预防的。首先，只有少数人 已知的细胞表面蛋白，其对癌症具有足够的特异性以安全地允许抗体靶向。这是 对于实体癌尤其如此，与造血系统恶性肿瘤不同， 容易被干细胞祖细胞补充。其次，由于每个个体的双特异性蛋白和/或CAR T细胞 如果一个人只能靶向单一癌症类型，则需要为每种癌症类型开发不同的双特异性和/或CAR T细胞， 癌症类型。这大大增加了开发时间和成本。第三，这两种疗法都不能有效地 靶向已知最丰富和广泛表达的癌症抗原，即肿瘤相关癌症 抗原（TACA）。许多癌症特异性抗原不是蛋白质，而是复杂的碳水化合物， 在正常组织中表达有限或无表达。事实上，糖基化改变是癌症的一个几乎普遍的特征。 然而，已经证明产生对复合碳水化合物特异的单克隆抗体是非常困难的。 具有挑战性，极大地限制了它们作为癌症免疫治疗靶点的有用性。在此，我们建议 解决这些问题，并开发一类新的免疫治疗药物， 大多数实体癌和造血系统癌共有的抗原，但在正常人中不表达。 细胞我们将这些分子称为聚糖依赖性T细胞募集（GlyTR）技术。 关键的是，GlyTR技术不利用抗体来靶向碳水化合物癌抗原。初步 数据表明，O-连接的碳水化合物靶向的双特异性GlyTR蛋白诱导T细胞依赖性 在体外杀死人癌细胞而不脱靶杀死正常细胞。为了进一步发展这项技术， 我们提出以下目标。目的1优化了O-连接聚糖靶向GlyTR双特异性蛋白， 活动和药物开发。目的2：探讨优化的O-聚糖的有效性和安全性 靶向GlyTR双特异性蛋白。如果成功的话，这项工作将导致IND能够研究一个全新的 一类可靶向多种实体癌和造血系统癌的免疫抗癌治疗剂 毒性最小。